This invention pertains to an anti-microbial, in particular anti-bacterial, more particularly against Gram negative bacteria, and/or anti-fungal composition comprising as active blend trans-cinnamaldehyde and a potentiating agent. In particular this composition is intended for preventing and/or treating microbial infection in an animal.

This invention pertains to an anti-microbial, in particular anti-bacterial, more particularly against Gram negative bacteria, and/or anti-fungal composition comprising as active blend trans-cinnamaldehyde and a potentiating agent. In particular this composition is intended for preventing and/or treating microbial infection in an animal.

This invention pertains to an anti-microbial, in particular anti-bacterial, more particularly against Gram negative bacteria, and/or anti-fungal composition comprising as active blend trans-cinnamaldehyde and a potentiating agent. In particular this composition is intended for preventing and/or treating microbial infection in an animal.

The present invention relates to a device and method for making sclerosing foam, which is useful in the treatment of varicose veins and other venous conditions. The device comprises a continuous pathway that is at least partly formed of flexible or compressible material and that comprises a foam generating structure within the continuous pathway; the foam generating structure being formed of two or more elements, wherein each element defines at least one passageway of cross sectional area 1 μm2 to 10 mm2 and said two or more elements being arranged in series; a port which allows introduction of material into or extraction of material out of the continuous pathway; and a liquid pathway that is at least partly formed of flexible or compressible material and is arranged to deliver liquid into the foam generating structure between a first and second element of the foam generating structure.

The present invention relates to a device and method for making sclerosing foam, which is useful in the treatment of varicose veins and other venous conditions. The device comprises a continuous pathway that is at least partly formed of flexible or compressible material and that comprises a foam generating structure within the continuous pathway; the foam generating structure being formed of two or more elements, wherein each element defines at least one passageway of cross sectional area 1 μm2 to 10 mm2 and said two or more elements being arranged in series; a port which allows introduction of material into or extraction of material out of the continuous pathway; and a liquid pathway that is at least partly formed of flexible or compressible material and is arranged to deliver liquid into the foam generating structure between a first and second element of the foam generating structure.

A method of inducing anesthesia in a subject is provided. In some embodiments, the method provides administering to the subject via the respiratory system or via injection, an effective amount of a compound or a mixture of compounds selected from the group consisting of methyl-ethyl ethers, methyl-isopropyl ethers, and methyl-propyl ethers.

A method of inducing anesthesia in a subject is provided. In some embodiments, the method provides administering to the subject via the respiratory system or via injection, an effective amount of a compound or a mixture of compounds selected from the group consisting of methyl-ethyl ethers, methyl-isopropyl ethers, and methyl-propyl ethers.

The present disclosure is directed to a method of treating a neuropsychiatric disorder. This method involves selecting a subject having the neuropsychiatric disorder and administering to the selected subject a preparation of glial progenitor cells at a dosage effective to treat the neuropsychiatric disorder in the subject. Another aspect of the disclosure is directed to a method of treating a neuropsychiatric disorder that includes selecting a subject having the neuropsychiatric disorder and administering, to the selected subject, a potassium (K.sup.+) channel activator at a dosage effective to restore normal brain interstitial glial K.sup.+ levels in the selected subject and treat the neuropsychiatric disorder is also disclosed.

One larger [1] and one smaller tube [2], forming a functional unit with the smaller tube [2] positioned within the larger tube [1], both tubes are relocatable and demountable, both tubes with an aperture [3 and 4] at both ends, at least one aperture [5] being provided in the wall of the outer tube located at a distance of about between 1 mm and 10 cm from the tip [6], or several apertures positioned in a segment of 1-250 mm from the tip, wherein the diameter of the single aperture is between 70% and 120% of the inner diameter of the outer tube [1], or in case of several apertures, for each aperture 30-60% of the inner diameter of the outer tube, wherein the outer diameter of the inner tube is between 0.6 mm and 2.0 mm (F2 to F6), the outer diameter of the outer tube is between 1.3 mm and 3.6 mm (F4 to F11), and the distance between the outer wall of the inner tube and the inner wall of the outer tube is between 0.1 mm to 3.0 mm.

One larger [1] and one smaller tube [2], forming a functional unit with the smaller tube [2] positioned within the larger tube [1], both tubes are relocatable and demountable, both tubes with an aperture [3 and 4] at both ends, at least one aperture [5] being provided in the wall of the outer tube located at a distance of about between 1 mm and 10 cm from the tip [6], or several apertures positioned in a segment of 1-250 mm from the tip, wherein the diameter of the single aperture is between 70% and 120% of the inner diameter of the outer tube [1], or in case of several apertures, for each aperture 30-60% of the inner diameter of the outer tube, wherein the outer diameter of the inner tube is between 0.6 mm and 2.0 mm (F2 to F6), the outer diameter of the outer tube is between 1.3 mm and 3.6 mm (F4 to F11), and the distance between the outer wall of the inner tube and the inner wall of the outer tube is between 0.1 mm to 3.0 mm.